Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease

Geetha Raghu; Aishwarya Karunanithi; Iyanar Kannan; Lakshmi Preetha K

doi:10.5455/njppp.2017.7.1038623102017

2026, Vol: 16, Issue: 1

16 / 1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 06 Nov 2017

Natl J Physiol Pharm Pharmacol. 2018; 8(2): 244-250

doi: 10.5455/njppp.2017.7.1038623102017

Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease

Geetha Raghu, Aishwarya Karunanithi, Iyanar Kannan, Lakshmi Preetha K.

Cited By:6

Abstract
Background: Alzheimers disease (AD) is a progressive neurodegenerative brain disorder, and it is the main cause of dementia in the elderly. At present, no proper cure is available to stop the progression of AD. The neuronal damage in AD is due to the deposition of β-amyloid peptide and tau protein within the brain. Curcumin a curry spice has several beneficial activities such as antioxidant, antimicrobial, anti-inflammatory, and chemotherapeutic properties.

Aims and Objectives: The main objective was to perform molecular docking of curcumin and its derivatives with BACE1 to determine its binding efficacy and the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the selected curcumin derivatives.

Materials and Methods: Three-dimensional structure of the BACE1 was retrieved from RCSB database in protein data bank format. Total 200 ligand derivatives of curcumin were generated using the software advanced chemistry development/ChemSketch. The rapid virtual screening of the compounds was performed using the docking tool iGEMDOCK version 2.0. The ligands with low binding energy were selected and were analyzed for the drug-relevant properties. The final docking of the ligands was performed using the software AutoDock 4.0, based on the drug-like properties and the binding affinity.

Results: Among the four ligands, based on the drug-likeness, the ligand (6Z)-1-(4-hydroxy-3-methoxy-2-nitrophenyl)-7-(4-hydroxy-3-methoxyohenyl) hepta-1,6-diene-3, 5-dione was the best. It had excellent binding energy with good ADMET properties.

Conclusion: In this study, using the molecular docking method, a new compound has been identified to inhibit BACE1. This compound can be an effective drug candidate for controlling AD.

Key words: Molecular Docking; Curcumin; Alzheimers Disease; BACE1

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Geetha Raghu Articles by Aishwarya Karunanithi Articles by Iyanar Kannan Articles by Lakshmi Preetha K
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Raghu G, Karunanithi A, Kannan I, K LP. Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. Natl J Physiol Pharm Pharmacol. 2018; 8(2): 244-250. doi:10.5455/njppp.2017.7.1038623102017

Web Style

Raghu G, Karunanithi A, Kannan I, K LP. Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. https://www.njppp.com/?mno=279934 [Access: June 26, 2026]. doi:10.5455/njppp.2017.7.1038623102017

AMA (American Medical Association) Style

Raghu G, Karunanithi A, Kannan I, K LP. Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. Natl J Physiol Pharm Pharmacol. 2018; 8(2): 244-250. doi:10.5455/njppp.2017.7.1038623102017

Vancouver/ICMJE Style

Raghu G, Karunanithi A, Kannan I, K LP. Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. Natl J Physiol Pharm Pharmacol. (2018), [cited June 26, 2026]; 8(2): 244-250. doi:10.5455/njppp.2017.7.1038623102017

Harvard Style

Raghu, G., Karunanithi, . A., Kannan, . I. & K, . L. P. (2018) Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. Natl J Physiol Pharm Pharmacol, 8 (2), 244-250. doi:10.5455/njppp.2017.7.1038623102017

Turabian Style

Raghu, Geetha, Aishwarya Karunanithi, Iyanar Kannan, and Lakshmi Preetha K. 2018. Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. National Journal of Physiology, Pharmacy and Pharmacology, 8 (2), 244-250. doi:10.5455/njppp.2017.7.1038623102017

Chicago Style

Raghu, Geetha, Aishwarya Karunanithi, Iyanar Kannan, and Lakshmi Preetha K. "Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease." National Journal of Physiology, Pharmacy and Pharmacology 8 (2018), 244-250. doi:10.5455/njppp.2017.7.1038623102017

MLA (The Modern Language Association) Style

Raghu, Geetha, Aishwarya Karunanithi, Iyanar Kannan, and Lakshmi Preetha K. "Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease." National Journal of Physiology, Pharmacy and Pharmacology 8.2 (2018), 244-250. Print. doi:10.5455/njppp.2017.7.1038623102017

APA (American Psychological Association) Style

Raghu, G., Karunanithi, . A., Kannan, . I. & K, . L. P. (2018) Molecular docking study on curcumin and its derivatives as inhibitors of BACE1 in the treatment of Alzheimers disease. National Journal of Physiology, Pharmacy and Pharmacology, 8 (2), 244-250. doi:10.5455/njppp.2017.7.1038623102017

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article